Pharma Earnings Preview: ANI and Amneal Set for Q4 2025 Growth Reports
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on rare disease expansion and biosimilar adoption. The broader earnings window also features updates from Fulgent Genetics and Alpha Metallurgical, highlighting a diverse landscape of diagnostic shifts and commodity pricing.